|
0
|
|
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.
(academic.oup.com)
|
Marcus JL
…
Christopoulos KA
Clinical Infectious Diseases
2026-02-25
|
#treatment
#prophylaxis
#policy
#hiv
#equity
|
|
0
|
|
Interferon-alpha Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial.
(academic.oup.com)
|
Yong MK
…
Slavin M
Clinical Infectious Diseases
2026-02-25
|
#infection
#covid-19
#immunity
#cancer
#prophylaxis
|
|
0
|
|
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant.
(academic.oup.com)
|
Papanicolaou GA
…
Badshah C
Clinical Infectious Diseases
2026-02-25
|
#infection
#immunity
#prophylaxis
#transplantation
#immunoassay
|
|
0
|
|
Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015-2023.
(academic.oup.com)
|
Le JN
…
Hoover KW
Clinical Infectious Diseases
2026-02-25
|
#epidemiology
#prophylaxis
#hiv
|
|
0
|
|
Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients.
(academic.oup.com)
|
Limaye AP
…
Haber B
Clinical Infectious Diseases
2026-02-25
|
#infection
#immunity
#prophylaxis
#transplantation
#cmv
|